Medical Tourism in Beijing, China: How International Patients Access Advanced Care
- MedBridgeNZ
- 11 hours ago
- 8 min read
Quick Answer
For international patients exploring cross-border healthcare, accessing tertiary institutions in Beijing involves navigating specific administrative and clinical requirements. Core pathways typically include:
Formatting and preparing medical records to meet the specific submission standards of the receiving Chinese institution.
Identifying potentially relevant hospitals, departments, or specialists based on the clinical scope documented in the submitted records.
Obtaining hospital-issued acceptance, pre-admission, or other supporting documentation that may be required for an S2 or another applicable visa pathway, depending on the consular post and individual circumstances.
Navigating direct billing networks available at designated international medical departments, subject to specific policy terms.
Clinical eligibility, admission criteria, and treatment timelines are determined exclusively by the receiving hospital.
Who This Guide Is For—and Who May Not Be Suitable
This medical tourism guide is designed for international patients and their families seeking to understand the administrative pathways for accessing advanced diagnostics, specialised surgical interventions, or specific clinical trials in Beijing, China.
However, cross-border medical travel is not suitable for everyone. Patients requiring emergency or ICU-level stabilisation, individuals with medical contraindications to long-haul air travel, or patients whose cases cannot be adequately assessed because required medical records are missing may not be suitable for institutional review or travel at that time.
Our Patient Care Team can explain which records are typically required for hospital submission, whether translation or document formatting may be needed, and what the administrative next steps may involve. Clinical eligibility and treatment decisions are made solely by the receiving hospital.
Understanding Cross-Border Administrative Terms
To navigate the system effectively, international patients must distinguish between administrative coordination and clinical guarantees.
Term | What It Means | What It Does Not Mean |
Remote record review | A hospital or specialist assesses submitted records. | The patient has been accepted for treatment. |
Hospital acceptance | The institution agrees to proceed with a defined next step (e.g., an in-person consultation). | A treatment outcome is guaranteed. |
Direct billing | The hospital may invoice an approved insurer directly. | Every charge is covered, or no deposit is required. |
Clinical trial | An investigational treatment conducted under a strict research protocol. | A commercial treatment readily available to all patients. |
Equipment configuration approval | Regulatory permission for a hospital to install specific medical equipment. | The service is currently operational and accepting international patients. |
Visa-free entry | Entry under a qualifying immigration policy for permitted purposes. | Guaranteed permission to enter specifically for long-term medical treatment. |
Approved Treatments vs. Clinical Trials
Patients managing refractory conditions often explore Beijing's tertiary centres where selected advanced therapies may be available through approved clinical services or regulated research programmes, depending on the diagnosis and institution.
It is crucial to understand the regulatory status of these modalities:
Modality | Regulatory/Clinical Status | What International Patients Should Know |
Commercial CAR-T for approved blood-cancer indications | Approved products may be available for narrowly defined indications. | Eligibility depends on diagnosis, prior therapies, organ function, and hospital acceptance. |
Satri-cel, a CLDN18.2-targeted CAR-T therapy | Approved in China in June 2026 for a narrowly defined indication involving CLDN18.2-positive, HER2-negative, unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma after failure of at least two prior lines of therapy. | Regulatory approval does not mean that every patient is eligible or that the therapy is available at every Beijing hospital. Biomarker testing, organ-function assessment, prior-treatment review, and institutional acceptance are required. |
Other CLDN18.2 CAR-T products or other tumour indications | Investigational unless separately approved for the specific product and indication. | Access may be limited to regulated clinical studies with protocol-specific eligibility criteria. |
In vivo CAR-T | Investigational. | Safety, efficacy, and access remain subject to early-stage clinical research. |
Proton therapy | Established radiotherapy modality, but local equipment and service availability vary. | Equipment approval does not automatically mean that treatment is operational or open to international patients. |
Evidence Snapshot: Satri-cel Regulatory and Evidence Status
Modality: Satricabtagene autoleucel, a CLDN18.2-targeted autologous CAR-T therapy.
Regulatory status: Approved in China in June 2026 for a narrowly defined gastric or gastro-oesophageal junction cancer indication.
Evidence base: Randomised, open-label, multicentre phase 2 trial.
Important limitation: Approval applies only to the labelled patient population and does not establish suitability, availability, or access at every institution.
Clinical decision-maker: The receiving hospital and treating oncology team.
(Status last checked: July 2026. Patients should confirm current product availability, treating-centre capability, international-patient acceptance, and any relevant clinical-trial recruitment directly with the institution.)
Medical Tourism in Beijing, China: Choosing the Right Care Pathway
Beijing operates a complex medical network, and international patients must choose the appropriate institutional pathway based on their clinical needs, insurance status, and preference for administrative support.
Beijing Care Pathway | Potential Advantages | Common Limitations |
Private international hospital | English-language environment, familiar international service processes, may offer broader direct-billing support. | Higher consultation and inpatient charges; some highly specialised treatments may require referral. |
Public tertiary hospital international department (IMS) | Access to major academic departments and specialised clinical teams. | Limited appointment capacity; insurance and language support vary by institution. |
Non-governmental tertiary hospital with international services | Combines tertiary infrastructure with dedicated international-patient services. | Specialist availability, pricing, and insurance arrangements are institution-specific. |
Standard public-hospital department | May offer access to specialised departments, sometimes with lower self-pay charges than dedicated international services. | Greater Chinese-language, registration and payment complexity; access routes and charges vary by department. |
To compare hospital types, international medical services, and major clinical focus areas, explore our featured hospitals in Beijing.
(Status last checked: July 2026. Patients should confirm current service availability directly with the institution before making travel arrangements.)
Medical Records Required for Preliminary Review
Receiving institutions have different documentation requirements. Some international departments accept English-language records, while others may request Chinese translations, structured medical summaries, pathology materials, or specific imaging formats. Requirements should be confirmed before submission. A typical dossier may include a recent medical summary, prior treatment and operative notes, pathology reports, laboratory results, and relevant imaging in DICOM format.
Costs and What Estimates Do Not Include
Published estimates suggest that some procedures in China may cost less than comparable self-funded care in certain private healthcare markets. However, international-patient pricing varies substantially by hospital department, specialist, treatment complexity, required implants, medicines, length of stay, and unforeseen complications.
Any figures encountered during initial research are illustrative only and are not official hospital quotations.
Regarding timelines, prolonged waiting periods in a patient's home country may influence the timing of evaluation or treatment planning; the clinical significance of any delay must be assessed by the patient’s treating physician. While some international departments in Beijing may be able to coordinate diagnostic testing or specialist reviews within a relatively short period after records are accepted, actual timing depends on clinical urgency, hospital capacity, required examinations, bed availability, and institutional scheduling. MedBridgeNZ cannot guarantee appointment, admission, or treatment dates.
Insurance and Direct Billing
Some International Medical Services departments and private facilities maintain direct-billing arrangements with selected international insurers. However, direct billing is available only where the hospital, insurer, and specific policy have an active arrangement.
The hospital may seek pre-authorisation or a Guarantee of Payment (GOP) from the insurer. The patient remains responsible for any deductible, co-payment, exclusion, or amount not approved by the insurer, and some hospitals may still request a deposit upon admission.
Representative Administrative Pathway
The following pathway illustrates the logistical steps for cross-border coordination. It does not describe a specific patient outcome.
Clinical Context: An individual diagnosed with a complex oncological condition explores international review options.
Records Prepared for Review: Diagnostic imaging and medical reports are formatted according to the receiving institution's language and file requirements.
Institutional Review Channel: The formatted dossier is submitted to an appropriate specialist, department, or multidisciplinary tumour board, where that service is available and clinically indicated.
Clinical Assessment: The receiving hospital evaluates whether sufficient information is available and whether the case falls within its clinical scope. It may request additional tests, recommend an in-person consultation, discuss an approved treatment option, consider eligibility for a clinical study, or decline to proceed.
Administrative Next Steps: If the hospital agrees to proceed, it may provide the acceptance, pre-admission, or other supporting documentation available under its institutional policies. The patient then prepares the financial and supporting documents required by the Chinese embassy, consulate, or visa application centre responsible for the application.
Frequently Asked Questions
Can international patients receive treatment at public hospitals in Beijing?
Some major public tertiary hospitals operate international medical departments or services that may accept international patients, subject to the institution’s policies, clinical scope and appointment availability. Access through standard public-hospital departments may also be possible in some cases, but commonly involves greater Chinese-language, registration and payment complexity.
Do Beijing hospitals accept English-language medical records?
Requirements vary by institution and department. Some international medical services accept English-language dossiers, while other departments may request Chinese translations, structured clinical summaries or specific imaging and pathology formats. Submission requirements should be confirmed before records are prepared.
Is satri-cel available to international patients in Beijing?
Approval in China does not establish availability at every Beijing institution or guarantee acceptance of international patients. Access depends on the treating centre, labelled eligibility criteria, product availability, clinical assessment, and the institution’s international-patient policies.
Can international health insurance be used at Beijing hospitals?
Some private facilities and IMS departments have direct-billing arrangements with selected global insurers. However, patients must usually obtain pre-authorisation or a Guarantee of Payment (GOP) beforehand. Non-covered items, deductibles, and co-payments remain the patient's responsibility.
How long does a preliminary hospital record review usually take?
The timeline depends heavily on the specific department, the availability of the specialists, and whether the submitted dossier is complete and formatted to the institution's standards. MedBridgeNZ cannot guarantee specific evaluation timelines.
Are any visa-free entry arrangements potentially relevant to short visits?
Eligible passport holders may qualify for China’s unilateral visa-free policy, subject to the permitted purposes and current entry rules. Separately, eligible travellers who are genuinely transiting to a third country or region may apply for the 240-hour visa-free transit arrangement. These policies do not guarantee hospital admission and should not be presented as dedicated medical-treatment visas. Travellers should not rely on the 240-hour visa-free transit arrangement for planned medical treatment without obtaining case-specific confirmation from the relevant Chinese immigration authority or the 12367 immigration service hotline. Eligible travellers can review our China visa-free entry guide for current nationality, duration, purpose, and itinerary considerations.
What financial evidence may be required for an S2 visa application related to medical treatment?
Requirements vary by consular post and individual case. Applicants may be asked to provide bank statements, a deposit certificate, proof of hospital acceptance, and evidence that they can cover anticipated medical and living expenses. Patients should confirm the current requirements with the Chinese embassy, consulate, or visa application centre responsible for their application. Final approval rests solely with the competent Chinese authorities.
For a more detailed overview of potential documentation and application steps, review our S1 and S2 visa application guide.
How MedBridgeNZ Coordinates the Process
Navigating the clinical and administrative landscape for advanced oncology care and complex surgical interventions requires structured coordination. Accessing major tertiary centres in Beijing involves overcoming language barriers, institutional formatting requirements, and strict immigration procedures.
Our Patient Care Team facilitates these administrative and logistical steps through our cross-border medical coordination services. We assist with medical dossier preparation, help identify potentially relevant departments based on the scope documented in the submitted records, and provide on-the-ground bilingual navigation once the receiving institution and patient have confirmed the travel plan.
Request an Administrative Case-Readiness Check
To understand what administrative steps are required to prepare your medical records for institutional review in Beijing, contact MedBridgeNZ to request an administrative case-readiness check.
References
Beijing Municipal Health Commission. “Notice on the Beijing International Medical Services Development, Reform and Innovation Work Plan.”https://wjw.beijing.gov.cn/zwgk_20040/ylws/202103/t20210311_2305128.html
Beijing Foreign Affairs Office. “Beijing Now Has 156 Medical Institutions Providing Full-Process Foreign-Language Services.”https://wb.beijing.gov.cn/home/dwhz/zczx/lqjs/202507/t20250728_4160417.html
Peking University International Hospital. “International Medical Center.”https://www.pkuih.edu.cn/specialized-center/details_1071_47848.html
Shanghai Observer. “World’s First Solid-Tumour CAR-T Therapy Approved in China, Offering a New Treatment Option for Advanced Gastric Cancer.”https://www.shobserver.cn/wx/detail.do?id=1132585
Peking University Health Science Center. “The Lancet: Shen Lin’s Team Leads the World’s First Randomised Controlled Study of CLDN18.2 CAR-T for Gastric Cancer.”https://research.bjmu.edu.cn/kydt/61d09fd0579749bf83098b448efa4d90.htm
National Health Commission of the People’s Republic of China. “Approved Configuration List for Proton and Heavy-Ion Radiotherapy Systems.”https://www.nhc.gov.cn/caiwusi/c100043/202402/965cd875d36f495685b98de5ee5bd76c/files/1733224073210_85164.pdf
Peking Union Medical College Hospital. “Partner Commercial Insurers for the International Medical Services Department, October 2025.”https://www.pumch.cn/department_ims/detail/24146.html
Ministry of Foreign Affairs of the People’s Republic of China. “Notice on Extending the Unilateral Visa-Free Policy.”https://www.mfa.gov.cn/wjbzwfwpt/kzx/tzgg/202511/t20251103_11746081.html
Beijing Capital International Airport. “240-Hour Visa-Free Transit Policy.”https://www.bcia.com.cn/mqzc.html
Written by: MedBridgeNZ Editorial Team
Editorial Review Scope: Administrative and cross-border coordination accuracy. Treatment-status statements were fact-checked against cited regulatory, institutional, and peer-reviewed sources. This article does not provide individual clinical recommendations.
Last reviewed: July 2026
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. MedBridgeNZ does not guarantee hospital acceptance, clinical eligibility, visa issuance, insurance authorisation, treatment availability, appointment dates, or medical outcomes. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options.
